Press Releases

Webcast
Q4 2017 Geron Earnings Conference Call
Mar 19, 2018 at 8:30 AM EDT
Webcast Presentation

Q4 2017 Geron Earnings Conference Call
Mar 19, 2018 at 8:30 AM EDT
Webcast
Geron at 17th Annual Needham Healthcare Conference
Mar 27, 2018 at 4:00 PM EDT
Webcast Presentation

Geron at 17th Annual Needham Healthcare Conference
Mar 27, 2018 at 4:00 PM EDT
Date Title and Summary  
Toggle Summary Studies Show Geron´s Stem Cell Therapeutic for Spinal Cord Injury Produces Nerve Growth Factors
Findings Published in Stem Cells and Development Indicate GRNOPC1 Promotes Survival and Regeneration of Neurons Damaged During Spinal Cord Injury MENLO PARK, Calif., Jan. 17, 2007 – Geron Corporation (Nasdaq: GERN) today reported that studies show GRNOPC1, the company’s human embryonic stem cell
Toggle Summary Geron Corporation to Present at BIO CEO & Investor Conference
MENLO PARK, Calif., Feb. 9, 2007 – Geron Corporation (Nasdaq: GERN) will present an update of the company’s product development programs at 1:15 p.m. ET on Monday, Feb. 12, 2007, at the BIO CEO & Investor Conference in New York City. The update of Geron’s portfolio of telomerase–based anti–cancer
Toggle Summary Unique Structure of Geron´s Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity in Lung Cancer Cells
MENLO PARK, Calif., Feb. 15, 2007 – Geron Corporation (Nasdaq: GERN) today announced the publication of preclinical data that show specific structural elements of GRN163L contribute to its unique anti–tumor and anti–metastatic activity. Published in Cancer Research (2007; 67: 1121–29), the studies
Toggle Summary Geron Corporation Announces Exercise Of Warrants for $15.0 Million of Proceeds
MENLO PARK, Calif., Feb. 27, 2007 – Geron Corporation (Nasdaq: GERN) today announced the exercise of warrants to purchase 1,875,000 shares of common stock at $8.00 per share for gross proceeds of $15.0 million. The exercised warrants were issued to institutional investors in connection with the
Toggle Summary Geron to Restate Financial Results of Prior Periods
No Impact on Reported Revenues, Operating Expenses, Total Assets or Cash Position MENLO PARK, Calif., March 9, 2007 – Geron Corporation (Nasdaq: GERN) today announced that the company will restate its financial statements for the 2005, 2004 and 2003 fiscal years as well as its quarterly financial
Toggle Summary Geron Grants License to Asia Biotech Corporation
Commercial License to Develop and Market Non–Therapeutic Products Using Telomerase Activators MENLO PARK, Calif., March 12, 2007 – Geron Corporation (Nasdaq: GERN) today announced it has granted an exclusive global license to Asia Biotech Corporation for the development of non–prescription dietary
Toggle Summary Geron Corporation Reports Fourth Quarter and Annual 2006 Financial Results and Highlights
Annual 2005, 2004 and 2003 Financial Statement Information Restated to Reflect Change in Warrant Classification as Previously Disclosed MENLO PARK, Calif., Mar. 16, 2007 – Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and year ended December 31, 2006.
Toggle Summary Geron Supports WARF´s Claims to Human Embryonic Stem Cell Patents
MENLO PARK, Calif., Apr. 2, 2007 – Geron Corporation (Nasdaq: GERN) supports the position of the Wisconsin Alumni Research Foundation (WARF) that U.S. patents covering Dr. James Thomson’s pioneering work with human embryonic stem cells were properly granted.
Toggle Summary Studies Confirm Proof-of-Principle for Geron´s Human Embryonic Stem Cell (hESC) Derived Hepatocytes
Findings Published in Cloning and Stem Cells Indicate Utility for Predictive Toxicology Tests MENLO PARK, Calif., April 19, 2007 – Geron Corporation (Nasdaq: GERN) announced today that it has developed standardized hepatocytes from human embryonic stem cells (hESCs) that can model human hepatic
Toggle Summary Geron and CXR Conclude Collaboration to Develop In Vitro Assays Using hESC-Derived Hepatocytes
MENLO PARK, Calif., and Dundee, Scotland, April 24, 2007 – Geron Corporation (Nasdaq: GERN) and CXR Biosciences Ltd. today announced the conclusion of a research collaboration that focused on the development of human embryonic stem cell (hESC)–derived hepatocytes for use in in vitro assays of drug